ciprofloxacin has been researched along with Inflammation in 40 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase II, randomised, double-blind, multicentre study (NCT00930982) investigated the safety and efficacy of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis." | 9.17 | Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. ( Alder, J; De Soyza, A; Greville, H; Hampel, B; O'Donnell, A; Polverino, E; Reimnitz, P; Welte, T; Wilson, R, 2013) |
| " The aim of this work was to assess the effect of broadspectrum antibiotics - combination of metronidazole and ciprofloxacin or metronidazole alone - on the intensity of intraocular inflammation in experimental autoimmune uveitis (EAU)." | 7.91 | Metronidazole Attenuates the Intensity of Inflammation in Experimental Autoimmune Uveitis. ( Dusek, O; Heissigerova, J; Klimova, A; Kucera, T; Seidler Stangova, P; Svozilkova, P, 2019) |
| "A 23-year old male with a history of schizophrenia treated with clozapine 900 mg/d was admitted to the hospital for a gastrointestinal infection." | 7.78 | A puzzling case of increased serum clozapine levels in a patient with inflammation and infection. ( Espnes, KA; Heimdal, KO; Spigset, O, 2012) |
| "Microglial inflammation is the hallmark of S." | 5.56 | Dexamethasone along with ciprofloxacin modulates S. aureus induced microglial inflammation via glucocorticoid (GC)-GC receptor-mediated pathway. ( Bishayi, B; Dey, R, 2020) |
| "Ciprofloxacin and celecoxib were used in combination to regulate S." | 5.48 | Combination treatment of celecoxib and ciprofloxacin attenuates live S. aureus induced oxidative damage and inflammation in murine microglia via regulation of cytokine balance. ( Bishayi, B; Dey, R; Sultana, S, 2018) |
| "Mice treated with ciprofloxacin (7." | 5.34 | Immunomodulatory effects of ciprofloxacin in TNBS-induced colitis in mice. ( Barazovsky, E; Fabian, I; Halperin, D; Klausner, J; Lahat, G; Rabau, M; Shalit, I, 2007) |
| "Granulomatous inflammation is a common component of many diseases." | 5.29 | Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. ( Hegemann, L; Toso, SM; Webster, GF, 1994) |
| "This phase II, randomised, double-blind, multicentre study (NCT00930982) investigated the safety and efficacy of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis." | 5.17 | Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. ( Alder, J; De Soyza, A; Greville, H; Hampel, B; O'Donnell, A; Polverino, E; Reimnitz, P; Welte, T; Wilson, R, 2013) |
| "Seventy-seven patients [25 with clinical suspicion of diabetic foot osteomyelitis (DFOM), 25 with orthopedic device-related infection (ODRI) and 27 with tubercular bone infection] underwent three-phase Tc-methylenediphosphonate bone scintigraphy followed by static Tc-ciprofloxacin imaging at 1, 4 and 24 h." | 5.13 | Efficacy of indigenously developed single vial kit preparation of 99mTc-ciprofloxacin in the detection of bacterial infection: an Indian experience. ( Aggarwal, S; Bhatnagar, A; Bhattacharya, A; Gill, SS; Goni, VG; Kashyap, R; Mittal, BR; Prasad, V; Rai, R; Sharma, S; Singh, AK; Singh, B; Sunil, HV; Taneja, A, 2008) |
| " The related optimal dose and time point of ciprofloxacin or indomethacin in response to macrophage inflammatory response inflammation were determined via macrophage secretion induced by LPS." | 4.12 | The combination of ciprofloxacin and indomethacin suppresses the level of inflammatory cytokines secreted by macrophages in vitro. ( Li, SY; Liu, K; Xia, Y; Yan, J; Yu, J; Zhang, LT, 2022) |
| " The aim of this work was to assess the effect of broadspectrum antibiotics - combination of metronidazole and ciprofloxacin or metronidazole alone - on the intensity of intraocular inflammation in experimental autoimmune uveitis (EAU)." | 3.91 | Metronidazole Attenuates the Intensity of Inflammation in Experimental Autoimmune Uveitis. ( Dusek, O; Heissigerova, J; Klimova, A; Kucera, T; Seidler Stangova, P; Svozilkova, P, 2019) |
| "An autofeedback complex polymeric platform was used in the design of an intelligent intraocular implant-the I(3)-using stimuli-responsive polymers, producing a smart release system capable of delivering therapeutic levels of an anti-inflammatory agent (indomethacin) and antibiotic (ciprofloxacin) for posterior segment disorders of the eye in response to inflammation." | 3.80 | In vitro, in vivo, and in silico evaluation of the bioresponsive behavior of an intelligent intraocular implant. ( Carmichael, T; Choonara, YE; du Toit, LC; Govender, T; Kumar, P; Pillay, V, 2014) |
| "A 23-year old male with a history of schizophrenia treated with clozapine 900 mg/d was admitted to the hospital for a gastrointestinal infection." | 3.78 | A puzzling case of increased serum clozapine levels in a patient with inflammation and infection. ( Espnes, KA; Heimdal, KO; Spigset, O, 2012) |
| " 99mTc-labeled ciprofloxacin does not distinguish between infections and sterile inflammatory lesions, which implies that its specificity for the detection of bacterial infections is not warranted." | 3.71 | 99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections. ( Balter, HS; Lanzzeri, S; Lupetti, A; Nibbering, PH; Paulusma-Annema, A; Pauwels, EK; Rey, AM; Savio, EO; Souto, B; Welling, MM, 2001) |
| "The aim of the study was to distinguish infection from inflammation in patients with suspected infection using technetium-99m Infecton." | 3.69 | Clinical evaluation of technetium-99m infecton for the localisation of bacterial infection. ( Bomanji, J; Britton, KE; Das, S; Hall, AV; Siraj, QH; Solanki, K; Vinjamuri, S, 1997) |
| "Neuroinflammation is the response of the central nervous system to events that interfere with tissue homeostasis and represents a common denominator in virtually all neurological diseases." | 2.61 | Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway. ( Franceschini, D; Frigo, AC; Giusti, P; Lo, R; Lunardi, V; Moro, S; Pagetta, A; Stifani, S; Zusso, M, 2019) |
| "Microglial inflammation is the hallmark of S." | 1.56 | Dexamethasone along with ciprofloxacin modulates S. aureus induced microglial inflammation via glucocorticoid (GC)-GC receptor-mediated pathway. ( Bishayi, B; Dey, R, 2020) |
| "Periodontitis is a common disease caused by plaque biofilms, which are important pathogenic factors of many diseases and may be eradicated by antibiotic therapy." | 1.51 | Dual Corona Vesicles with Intrinsic Antibacterial and Enhanced Antibiotic Delivery Capabilities for Effective Treatment of Biofilm-Induced Periodontitis. ( Du, J; Gao, J; Wang, Y; Xi, Y; Xiao, Y, 2019) |
| "Ciprofloxacin and celecoxib were used in combination to regulate S." | 1.48 | Combination treatment of celecoxib and ciprofloxacin attenuates live S. aureus induced oxidative damage and inflammation in murine microglia via regulation of cytokine balance. ( Bishayi, B; Dey, R; Sultana, S, 2018) |
| "Ciprofloxacin is an antibacterial agent used mainly in urinary tract infections and prostate inflammation." | 1.38 | Ciprofloxacin as a prophylactic agent against prostate cancer: a "two hit" hypothesis. ( Bajek, A; Drewa, T; Gurtowska, N; Kloskowski, T, 2012) |
| "Chloramphenicol was effective against most of the Gram-positive organisms." | 1.35 | Clinicobacteriological study of chronic dacryocystitis in adults. ( Banerjee, AR; Biswas, MC; Kundu, PK; Mandal, R; Mondal, A; Sasmal, NK, 2008) |
| "Mice treated with ciprofloxacin (7." | 1.34 | Immunomodulatory effects of ciprofloxacin in TNBS-induced colitis in mice. ( Barazovsky, E; Fabian, I; Halperin, D; Klausner, J; Lahat, G; Rabau, M; Shalit, I, 2007) |
| "Sepsis was induced by cecal ligation and puncture (CLP) in Swiss mice using an 18-gauge needle." | 1.32 | Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. ( Amâncio, RT; Bozza, FA; Bozza, PT; Castro-Faria-Neto, HC; David, CM; Gomes, RN; Vianna, RC, 2004) |
| "Granulomatous inflammation is a common component of many diseases." | 1.29 | Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. ( Hegemann, L; Toso, SM; Webster, GF, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.50) | 18.7374 |
| 1990's | 5 (12.50) | 18.2507 |
| 2000's | 10 (25.00) | 29.6817 |
| 2010's | 17 (42.50) | 24.3611 |
| 2020's | 7 (17.50) | 2.80 |
| Authors | Studies |
|---|---|
| Tonk, RK | 1 |
| Bawa, S | 1 |
| Chawla, G | 1 |
| Deora, GS | 1 |
| Kumar, S | 1 |
| Rathore, V | 1 |
| Mulakayala, N | 1 |
| Rajaram, A | 1 |
| Kalle, AM | 1 |
| Afzal, O | 1 |
| Wang, Y | 2 |
| Carion, TW | 1 |
| Ebrahim, AS | 1 |
| Sosne, G | 1 |
| Berger, EA | 1 |
| Parpoudi, S | 1 |
| Mantzoros, I | 1 |
| Gkiouliava, A | 1 |
| Kyziridis, D | 1 |
| Makrantonakis, A | 1 |
| Chatzakis, C | 1 |
| Gekas, C | 1 |
| Konstantaras, D | 1 |
| Ioannidis, O | 1 |
| Bitsianis, S | 1 |
| Miliaras, D | 1 |
| Aggelopoulos, S | 1 |
| Liu, K | 1 |
| Yu, J | 1 |
| Xia, Y | 1 |
| Zhang, LT | 1 |
| Li, SY | 1 |
| Yan, J | 1 |
| Li, M | 1 |
| Yu, L | 1 |
| Zhai, Q | 1 |
| Chu, C | 1 |
| Wang, S | 1 |
| Zhao, J | 1 |
| Zhang, H | 1 |
| Tian, F | 1 |
| Chen, W | 1 |
| Xi, Y | 1 |
| Gao, J | 1 |
| Xiao, Y | 1 |
| Du, J | 1 |
| Bohossian, HB | 1 |
| Lopes, EW | 1 |
| Roller, LA | 1 |
| Ananthakrishnan, AN | 1 |
| Zukerberg, LR | 1 |
| Dey, R | 2 |
| Bishayi, B | 3 |
| Seidler Stangova, P | 1 |
| Dusek, O | 1 |
| Klimova, A | 1 |
| Heissigerova, J | 1 |
| Kucera, T | 1 |
| Svozilkova, P | 1 |
| Kayal, M | 1 |
| Bhagya Rao, B | 1 |
| Bhattacharya, A | 2 |
| Ungaro, R | 1 |
| Sultana, S | 1 |
| Haque, S | 1 |
| Feeney, O | 1 |
| Meeusen, E | 1 |
| Boyd, BJ | 1 |
| McIntosh, MP | 1 |
| Pouton, CW | 1 |
| Whittaker, M | 1 |
| Kaminskas, LM | 1 |
| Zusso, M | 1 |
| Lunardi, V | 1 |
| Franceschini, D | 1 |
| Pagetta, A | 1 |
| Lo, R | 1 |
| Stifani, S | 1 |
| Frigo, AC | 1 |
| Giusti, P | 1 |
| Moro, S | 1 |
| du Toit, LC | 1 |
| Carmichael, T | 1 |
| Govender, T | 1 |
| Kumar, P | 1 |
| Choonara, YE | 1 |
| Pillay, V | 1 |
| Patel, K | 1 |
| Lamb, B | 1 |
| Pathak, S | 1 |
| Peters, J | 1 |
| Dey, S | 1 |
| Majhi, A | 1 |
| Mahanti, S | 1 |
| Dey, I | 1 |
| Ferreira, AS | 1 |
| Silva, IN | 1 |
| Fernandes, F | 1 |
| Pilkington, R | 1 |
| Callaghan, M | 1 |
| McClean, S | 1 |
| Moreira, LM | 1 |
| Sung, PH | 1 |
| Chiang, HJ | 1 |
| Chen, CH | 1 |
| Chen, YL | 2 |
| Huang, TH | 1 |
| Zhen, YY | 1 |
| Chang, MW | 1 |
| Liu, CF | 1 |
| Chung, SY | 1 |
| Chai, HT | 1 |
| Sun, CK | 1 |
| Yip, HK | 1 |
| Sibila, O | 1 |
| Luna, CM | 1 |
| Agustí, C | 1 |
| Baquero, S | 1 |
| Gando, S | 1 |
| Patrón, JR | 1 |
| Morato, JG | 1 |
| Absi, R | 1 |
| Bassi, N | 1 |
| Torres, A | 1 |
| Mandal, R | 1 |
| Banerjee, AR | 1 |
| Biswas, MC | 1 |
| Mondal, A | 1 |
| Kundu, PK | 1 |
| Sasmal, NK | 1 |
| Singh, B | 1 |
| Sunil, HV | 1 |
| Sharma, S | 1 |
| Prasad, V | 1 |
| Kashyap, R | 1 |
| Mittal, BR | 1 |
| Taneja, A | 1 |
| Rai, R | 1 |
| Goni, VG | 1 |
| Aggarwal, S | 1 |
| Gill, SS | 1 |
| Bhatnagar, A | 1 |
| Singh, AK | 1 |
| Paganelli, F | 1 |
| Cardillo, JA | 1 |
| Melo, LA | 1 |
| Lucena, DR | 1 |
| Silva, AA | 1 |
| Oliveira, AG | 1 |
| Höfling-Lima, AL | 1 |
| Nguyen, QD | 1 |
| Kuppermann, BD | 1 |
| Belfort, R | 1 |
| Brandon, JA | 1 |
| Jennings, CD | 1 |
| Kaplan, AM | 1 |
| Bryson, JS | 1 |
| Kloskowski, T | 1 |
| Gurtowska, N | 1 |
| Bajek, A | 1 |
| Drewa, T | 1 |
| Kim, SH | 1 |
| Ha, US | 1 |
| Sohn, DW | 1 |
| Lee, SJ | 1 |
| Kim, HW | 1 |
| Han, CH | 1 |
| Cho, YH | 1 |
| Espnes, KA | 1 |
| Heimdal, KO | 1 |
| Spigset, O | 1 |
| Wilson, R | 1 |
| Welte, T | 1 |
| Polverino, E | 1 |
| De Soyza, A | 1 |
| Greville, H | 1 |
| O'Donnell, A | 1 |
| Alder, J | 1 |
| Reimnitz, P | 1 |
| Hampel, B | 1 |
| Li, HW | 1 |
| Sachs, J | 1 |
| Pichardo, C | 1 |
| Bronson, R | 1 |
| Zhao, G | 1 |
| Sykes, M | 1 |
| Vianna, RC | 1 |
| Gomes, RN | 1 |
| Bozza, FA | 1 |
| Amâncio, RT | 1 |
| Bozza, PT | 1 |
| David, CM | 1 |
| Castro-Faria-Neto, HC | 1 |
| Oyen, WJ | 1 |
| Corstens, FH | 1 |
| Boerman, OC | 1 |
| Tiainen, J | 1 |
| Soini, Y | 1 |
| Suokas, E | 1 |
| Veiranto, M | 1 |
| Törmälä, P | 1 |
| Waris, T | 1 |
| Ashammakhi, N | 1 |
| Lahat, G | 1 |
| Halperin, D | 1 |
| Barazovsky, E | 1 |
| Shalit, I | 1 |
| Rabau, M | 1 |
| Klausner, J | 1 |
| Fabian, I | 1 |
| Webster, GF | 1 |
| Toso, SM | 1 |
| Hegemann, L | 1 |
| Yamagishi, M | 1 |
| Harada, H | 1 |
| Kurihara, M | 1 |
| Shijubo, N | 1 |
| Satoh, M | 1 |
| Kumagai, M | 1 |
| Abe, S | 1 |
| Hurst, RD | 1 |
| Molinari, M | 1 |
| Chung, TP | 1 |
| Rubin, M | 1 |
| Michelassi, F | 1 |
| Britton, KE | 1 |
| Vinjamuri, S | 1 |
| Hall, AV | 1 |
| Solanki, K | 1 |
| Siraj, QH | 1 |
| Bomanji, J | 1 |
| Das, S | 1 |
| McKellar, Q | 1 |
| Gibson, I | 1 |
| Monteiro, A | 1 |
| Bregante, M | 1 |
| Welling, MM | 1 |
| Lupetti, A | 1 |
| Balter, HS | 1 |
| Lanzzeri, S | 1 |
| Souto, B | 1 |
| Rey, AM | 1 |
| Savio, EO | 1 |
| Paulusma-Annema, A | 1 |
| Pauwels, EK | 1 |
| Nibbering, PH | 1 |
| Acheson, DW | 1 |
| Sears, CL | 1 |
| Wise, R | 1 |
| Donovan, IA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Comparative Study of a Single Intraoperative Sub-Tenon's Capsule Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System Versus 1% Prednisolone and 0.3% Ciprofloxacin Eyedrops for Cataract Surgery[NCT00431028] | Phase 1/Phase 2 | 140 participants (Actual) | Interventional | 2005-09-30 | Terminated (stopped due to Terminated) | ||
| Randomized, Placebo-controlled, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Ciprofloxacin Inhale Compared to Placebo in Patients With Non-cystic Fibrosis Bronchiectasis[NCT00930982] | Phase 2 | 124 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis[NCT00583531] | Phase 2 | 2 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Lack of enrollment) | ||
| "A Phase 1b/2 Study to Demonstrate the Safety and Efficacy of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an Ileal Pouch-Anal Anastomosis (PROF). The PROF Study."[NCT05938465] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2023-10-11 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total bacterial load was determined in sputum collected before the inhalation of study drug. Sputum samples were either provided by the participant during the respective study visit, or participants had to bring a sputum sample that had been produced within the 4 hours prior to the visit. Induced sputum samples could be collected if the participant was unable to produce a spontaneously expectorated sputum sample of > 2 mL. Imputation method: last observation carried forward (LOCF). CFU: colony forming units, log10: decadic logarithm (NCT00930982)
Timeframe: Baseline and 29 days
| Intervention | log10 of CFU per gram sputum (Mean) |
|---|---|
| Ciprofloxacin Inhale (BAYQ3939) | -2.94 |
| Placebo | -0.32 |
Acute exacerbation was defined according to the joint American Thoracic Society/European Respiratory Society criteria. For detailed information with regard to this definition of acute exacerbation, please refer to the detailed description in the protocol section. The time to an acute exacerbation with antibiotic intervention was determined. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Days (Median) |
|---|---|
| Ciprofloxacin Inhale (BAYQ3939) | NA |
| Placebo | NA |
Participants were asked to start 24-hour sputum collection samples 24 hours before coming for the respective study visit. Sputum color was assessed as either 'clear', or as 'yellow', 'green' or 'rust', or an assessment of 'no sputum' was made. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 | Day 8 | Day 29 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 91.7 | 73.2 | 75.5 | 72.8 | 75.0 | 66.6 |
| Placebo | 88.9 | 94.9 | 82.7 | 88.4 | 86.5 | 72.8 |
Participants were asked to start 24-hour sputum collection samples 24 hours before coming for the respective study visit. The volume of the completed sample was determined. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | mL (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 1 | Day 8 | Day 29 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 24.9 | 18.9 | 20.5 | 21.1 | 19.6 | 23.6 |
| Placebo | 30.2 | 30.0 | 27.3 | 22.8 | 22.0 | 25.9 |
Absolute neutrophil count (ANC) was determined from safety blood samples. Missing or invalid values were replaced with the last valid value available. (NCT00930982)
Timeframe: Baseline and up to Day 42
| Intervention | giga/L (Mean) | ||
|---|---|---|---|
| Day 8 | Day 29 | Day 42 | |
| Ciprofloxacin Inhale (BAYQ3939) | -0.35 | -0.36 | -0.28 |
| Placebo | -0.03 | 0.59 | 0.24 |
Pulmonary function testing (spirometry) was conducted in accordance with American Thoracic Society standards. FEV1 was defined as the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS). Imputation method: last observation carried forward (LOCF). (NCT00930982)
Timeframe: Baseline and up to end of study (planned at Day 84)
| Intervention | Percent of predicted FEV1 (Mean) | ||||
|---|---|---|---|---|---|
| Day 8 | Day 29 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | -0.67 | -0.53 | 1.19 | 0.81 | 0.70 |
| Placebo | -0.14 | -0.22 | -0.26 | -0.24 | -0.50 |
Pulmonary function testing (spirometry) was conducted in accordance with American Thoracic Society standards. FVC was defined as the maximal volume of air exhaled with maximally forced effort from a maximal inspiration, i.e. vital capacity performed with a maximally forced expiratory effort expressed in liters at BTPS. Imputation method: last observation carried forward (LOCF). (NCT00930982)
Timeframe: Baseline and up to end of study (planned at Day 84)
| Intervention | Percent of predicted FVC (Mean) | ||||
|---|---|---|---|---|---|
| Day 8 | Day 29 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | -0.33 | -0.76 | 0.92 | 0.36 | -0.01 |
| Placebo | 0.04 | -1.05 | -1.09 | -1.16 | -1.99 |
High sensitive C-reactive protein (hsCRP) was determined from safety blood samples. Missing or invalid values were replaced with the last valid value available. (NCT00930982)
Timeframe: Baseline and up to Day 42
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| Day 8 | Day 29 | Day 42 | |
| Ciprofloxacin Inhale (BAYQ3939) | -0.43 | 0 | -0.16 |
| Placebo | -0.19 | 0 | 0.12 |
Total bacterial load was determined in sputum collected before the inhalation of study drug. Sputum samples were either provided by the participant during the respective study visit, or participants had to bring a sputum sample that had been produced within the 4 hours prior to the visit. Induced sputum samples could be collected if the participant was unable to produce a spontaneously expectorated sputum sample of > 2 mL on Day 8. Imputation method: last observation carried forward (LOCF). CFU: colony forming units, log10: decadic logarithm (NCT00930982)
Timeframe: Baseline and up to end of study (planned at Day 84)
| Intervention | log10 of CFU per gram sputum (Mean) | |||
|---|---|---|---|---|
| Day 8 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | -2.87 | -1.86 | -1.86 | -1.37 |
| Placebo | -0.20 | -0.31 | -0.21 | -0.24 |
Participants completed the Chronic Respiratory Questionnaire - Self Administered Standardized (CRQ-SAS). They were assured that all data would be treated confidentially and that the answers would not have any influence on study drug treatment. Participants completed the questionnaires on their own in a quiet area, without discussing them with study staff or accompanying persons (e.g. friends or relatives) and before being seen by the clinician. The score ranges between 1 and 7, 1 being the worst possible score. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Total score on a scale (Mean) | |||
|---|---|---|---|---|
| Day 1 | Day 29 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 4.88 | 4.99 | 4.94 | 5.01 |
| Placebo | 4.96 | 4.93 | 4.91 | 4.99 |
Participants completed the Saint George's Respiratory Questionnaire (SGRQ). They were assured that all data would be treated confidentially and that the answers would not have any influence on study drug treatment. Participants completed the questionnaires on their own in a quiet area, without discussing them with study staff or accompanying persons (e.g. friends or relatives) and before being seen by the clinician. The score ranges from 0 to 100 with 100 being the worst possible score. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Day 1 | Day 29 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 43.8 | 41.5 | 40.6 | 40.6 |
| Placebo | 44.7 | 44.8 | 44.1 | 41.6 |
The emergence of new potential respiratory pathogens was evaluated using microbiological analysis. Evaluated was the cumulative number of participants with first appearance of new potential respiratory antigens at each time point. In some cases, participants attended the end of study visit later than Day 84 (up to Day 88). (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Cumulative participants (Number) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 4 | Day 5 | Day 7 | Day 8 | Day 9 | Day 10 | Day 14 | Day 15 | Day 28 | Day 29 | Day 30 | Day 36 | Day 39 | Day 42 | Day 43 | Day 44 | Day 45 | Day 57 | Day 58 | Day 59 | Day 78 | Day 83 | Day 84 | Day 85 | Day 86 | Day 88 | |
| Ciprofloxacin Inhale (BAYQ3939) | 1 | 1 | 2 | 7 | 7 | 7 | 7 | 7 | 7 | 12 | 14 | 15 | 16 | 18 | 21 | 25 | 26 | 29 | 29 | 30 | 31 | 32 | 33 | 38 | 41 | 43 |
| Placebo | 0 | 2 | 2 | 8 | 10 | 11 | 12 | 13 | 14 | 24 | 30 | 30 | 31 | 33 | 38 | 40 | 41 | 45 | 46 | 47 | 47 | 47 | 47 | 53 | 54 | 54 |
The emergence of resistance (at least two-fold increase of Minimal inhibitory concentration, MIC, vs. baseline values) probably or possibly related to study medication among baseline pathogens was evaluated using microbiological analysis. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Emergence (>= 2* increase of MIC) | Sustained (>= 2* increase of MIC until end) | Transient (Increase in MIC with normalization) | Insufficient follow up | |
| Ciprofloxacin Inhale (BAYQ3939) | 7 | 1 | 5 | 1 |
| Placebo | 1 | 0 | 1 | 0 |
Microbiological response was defined as reduction in bacterial load or eradication (measured as the percentage of participants with positive culture). Missing values were not imputed. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 | Day 8 | Day 29 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 100.0 | 52.4 | 65.0 | 83.3 | 87.1 | 85.2 |
| Placebo | 100.0 | 88.2 | 91.8 | 86.8 | 96.4 | 92.0 |
Microbiological response was defined as reduction in bacterial load or eradication (measured as the number of participants with positive culture). Missing values were not imputed. Pathogens analyzed: Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Serratia marcescens, Pseudomonas aeruginosa, mucoid, Pseudomonas aeruginosa, non mucoid, Stenotrophomonas maltophilia, Achromobacter xylosoxydans, Moraxella catarrhalis, Haemophilus influenzae (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S. aureus Day 1 | S. aureus Day 8 | S. aureus Day 29 | S. aureus Day 42 | S. aureus Day 56 | S. aureus Day 84 | S. pneumoniae Day 1 | S. pneumoniae Day 8 | S. pneumoniae Day 29 | S. pneumoniae Day 42 | S. pneumoniae Day 56 | S. pneumoniae Day 84 | E. coli Day 1 | E. coli Day 8 | E. coli Day 29 | E. coli Day 42 | E. coli Day 56 | E. coli Day 84 | K. pneumoniae Day 1 | K. pneumoniae Day 8 | K. pneumoniae Day 29 | K. pneumoniae Day 42 | K. pneumoniae Day 56 | K. pneumoniae Day 84 | K. oxytoca Day 1 | K. oxytoca Day 8 | K. oxytoca Day 29 | K. oxytoca Day 42 | K. oxytoca Day 56 | K. oxytoca Day 84 | P. mirabilis Day 1 | P. mirabilis Day 8 | P. mirabilis Day 29 | P. mirabilis Day 42 | P. mirabilis Day 56 | P. mirabilis Day 84 | S. marcescens Day 1 | S. marcescens Day 8 | S. marcescens Day 29 | S. marcescens Day 42 | S. marcescens Day 56 | S. marcescens Day 84 | P. aeruginosa, mucoid Day 1 | P. aeruginosa, mucoid Day 8 | P. aeruginosa, mucoid Day 29 | P. aeruginosa, mucoid Day 42 | P. aeruginosa, mucoid Day 56 | P. aeruginosa, mucoid Day 84 | P. aeruginosa, non mucoid Day 1 | P. aeruginosa, non mucoid Day 8 | P. aeruginosa, non mucoid Day 29 | P. aeruginosa, non mucoid Day 42 | P. aeruginosa, non mucoid Day 56 | P. aeruginosa, non mucoid Day 84 | S. maltophilia Day 1 | S. maltophilia Day 8 | S. maltophilia Day 29 | S. maltophilia Day 42 | S. maltophilia Day 56 | S. maltophilia Day 84 | A. xylosoxydans Day 1 | A. xylosoxydans Day 8 | A. xylosoxydans Day 29 | A. xylosoxydans Day 42 | A. xylosoxydans Day 56 | A. xylosoxydans Day 84 | M. catarrhalis Day 1 | M. catarrhalis Day 8 | M. catarrhalis Day 29 | M. catarrhalis Day 42 | M. catarrhalis Day 56 | M. catarrhalis Day 84 | H. influenzae Day 1 | H. influenzae Day 8 | H. influenzae Day 29 | H. influenzae Day 42 | H. influenzae Day 56 | H. influenzae Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 8 | 4 | 5 | 6 | 8 | 5 | 7 | 2 | 0 | 3 | 1 | 1 | 2 | 2 | 2 | 0 | 1 | 1 | 5 | 0 | 0 | 0 | 1 | 3 | 3 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 2 | 12 | 7 | 9 | 9 | 6 | 4 | 20 | 6 | 10 | 12 | 10 | 13 | 2 | 0 | 2 | 2 | 4 | 1 | 2 | 2 | 2 | 2 | 1 | 0 | 5 | 0 | 0 | 1 | 1 | 1 | 14 | 1 | 1 | 1 | 3 | 4 |
| Placebo | 17 | 7 | 10 | 9 | 5 | 5 | 2 | 4 | 4 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 2 | 1 | 1 | 1 | 4 | 3 | 1 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 2 | 0 | 16 | 15 | 16 | 12 | 6 | 5 | 19 | 17 | 14 | 12 | 9 | 6 | 3 | 3 | 3 | 1 | 3 | 1 | 3 | 2 | 1 | 0 | 1 | 2 | 3 | 3 | 6 | 2 | 2 | 2 | 16 | 12 | 11 | 7 | 8 | 8 |
1 review available for ciprofloxacin and Inflammation
| Article | Year |
|---|---|
Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway.
Topics: Animals; Anti-Inflammatory Agents; Ciprofloxacin; Humans; Inflammation; Levofloxacin; Mice; Microgli | 2019 |
3 trials available for ciprofloxacin and Inflammation
| Article | Year |
|---|---|
Efficacy of indigenously developed single vial kit preparation of 99mTc-ciprofloxacin in the detection of bacterial infection: an Indian experience.
Topics: Adolescent; Adult; Bacterial Infections; Bone Diseases, Infectious; Ciprofloxacin; Diabetic Foot; Di | 2008 |
A single intraoperative sub-tenon's capsule injection of triamcinolone and ciprofloxacin in a controlled-release system for cataract surgery.
Topics: Aged; Anterior Chamber; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; Connective T | 2009 |
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bacterial Load; Bronchiectasis; Ciprofloxac | 2013 |
36 other studies available for ciprofloxacin and Inflammation
| Article | Year |
|---|---|
Synthesis and pharmacological evaluation of pyrazolo[4,3-c]cinnoline derivatives as potential anti-inflammatory and antibacterial agents.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Carrageenan; Cycloox | 2012 |
Adjunctive Thymosin Beta-4 Treatment Influences MΦ Effector Cell Function to Improve Disease Outcome in
Topics: Animals; Ciprofloxacin; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Inflammation; | 2021 |
Effect of N-acetyl-L-cysteine on inflammation after intraperitoneal mesh placement in a potentially contaminated environment: An experimental study in the rat.
Topics: Acetylcysteine; Animals; Ciprofloxacin; Inflammation; Interleukin-6; Male; Rats; Rats, Wistar; Surgi | 2022 |
The combination of ciprofloxacin and indomethacin suppresses the level of inflammatory cytokines secreted by macrophages in vitro.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Ciprofloxacin; Cytokines; Humans; Indometh | 2022 |
Combined
Topics: Bacteria; Ciprofloxacin; Gastrointestinal Microbiome; Humans; Inflammation; Occludin; Polysaccharide | 2023 |
Dual Corona Vesicles with Intrinsic Antibacterial and Enhanced Antibiotic Delivery Capabilities for Effective Treatment of Biofilm-Induced Periodontitis.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Drug Carriers; Drug Delivery Systems; Esche | 2019 |
Case 8-2020: An 89-Year-Old Man with Recurrent Abdominal Pain and Bloody Stools.
Topics: Abdominal Pain; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Clostridium Infections; Col | 2020 |
Dexamethasone along with ciprofloxacin modulates S. aureus induced microglial inflammation via glucocorticoid (GC)-GC receptor-mediated pathway.
Topics: Animals; Ciprofloxacin; Dexamethasone; Glucocorticoids; Inflammation; Mice; Microglia; Receptors, Gl | 2020 |
Metronidazole Attenuates the Intensity of Inflammation in Experimental Autoimmune Uveitis.
Topics: Animals; Ciprofloxacin; Female; Inflammation; Metronidazole; Mice, Inbred C57BL; Severity of Illness | 2019 |
Clinical Challenge: From Ulcerative Colitis to Crohn's Disease-Like Pouch Inflammation.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; Colitis, Ulcerative; Crohn Di | 2021 |
Combination treatment of celecoxib and ciprofloxacin attenuates live S. aureus induced oxidative damage and inflammation in murine microglia via regulation of cytokine balance.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Differentia | 2018 |
Local inflammation alters the lung disposition of a drug loaded pegylated liposome after pulmonary dosing to rats.
Topics: Animals; Anti-Bacterial Agents; Bleomycin; Bronchoalveolar Lavage Fluid; Ciprofloxacin; Cytokines; I | 2019 |
In vitro, in vivo, and in silico evaluation of the bioresponsive behavior of an intelligent intraocular implant.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Ciprofloxacin; Computer Simulation; Drug D | 2014 |
Vasitis: the need for imaging and clinical acumen.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Clindamycin; Diagnosis, Differential; Follow-Up Studies; Genit | 2014 |
In Vitro Anti-inflammatory and Immunomodulatory Effects of Ciprofloxacin or Azithromycin in Staphylococcus aureus-Stimulated Murine Macrophages are Beneficial in the Presence of Cytochalasin D.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antioxidants; Azithromycin; Ciprofloxacin; | 2015 |
The tyrosine kinase BceF and the phosphotyrosine phosphatase BceD of Burkholderia contaminans are required for efficient invasion and epithelial disruption of a cystic fibrosis lung epithelial cell line.
Topics: Albumins; Anti-Bacterial Agents; Bacterial Adhesion; Burkholderia cepacia complex; Burkholderia Infe | 2015 |
Combined Therapy With Adipose-Derived Mesenchymal Stem Cells and Ciprofloxacin Against Acute Urogenital Organ Damage in Rat Sepsis Syndrome Induced by Intrapelvic Injection of Cecal Bacteria.
Topics: Adipose Tissue; Animals; Apoptosis; Bacteria; Biomarkers; Ciprofloxacin; Disease Models, Animal; Hum | 2016 |
Effects of glucocorticoids in ventilated piglets with severe pneumonia.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bronchoalveolar Lavage; Ciprofloxacin; Diseas | 2008 |
Clinicobacteriological study of chronic dacryocystitis in adults.
Topics: Adult; Age Factors; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Chloramphenicol; Chronic Dis | 2008 |
Murine syngeneic graft-versus-host disease is responsive to broad-spectrum antibiotic therapy.
Topics: Animals; Anti-Bacterial Agents; Bone Marrow Transplantation; CD4-Positive T-Lymphocytes; Cell Line; | 2011 |
Ciprofloxacin as a prophylactic agent against prostate cancer: a "two hit" hypothesis.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Bacterial Infection | 2012 |
Preventive effect of ginsenoid on chronic bacterial prostatitis.
Topics: Animals; Anti-Bacterial Agents; Body Weight; Ciprofloxacin; Colony Count, Microbial; Inflammation; M | 2012 |
A puzzling case of increased serum clozapine levels in a patient with inflammation and infection.
Topics: Adult; Anti-Bacterial Agents; Antipsychotic Agents; Ciprofloxacin; Clozapine; Drug Interactions; Dru | 2012 |
Nonalloreactive T cells prevent donor lymphocyte infusion-induced graft-versus-host disease by controlling microbial stimuli.
Topics: Animals; Ciprofloxacin; Graft vs Host Disease; Inflammation; Lymphocyte Transfusion; Lymphopenia; Me | 2012 |
Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cecum; Ciprofloxacin; Clindamycin; Colony-For | 2004 |
Discriminating infection from sterile inflammation: can radiolabelled antibiotics solve the problem?
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Diagnosis, Differential; Fluorine Radioi | 2005 |
Tissue reactions to bioabsorbable ciprofloxacin-releasing polylactide-polyglycolide 80/20 screws in rabbits' cranial bone.
Topics: Animals; Anti-Infective Agents; Bone Screws; Ciprofloxacin; Drug Delivery Systems; Inflammation; Lac | 2006 |
Immunomodulatory effects of ciprofloxacin in TNBS-induced colitis in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Ceftazidime; Ciprofloxacin; Colitis; Colon | 2007 |
Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C.
Topics: Cells, Cultured; Ciprofloxacin; Dose-Response Relationship, Drug; Granuloma; Humans; Inflammation; M | 1994 |
Inflammatory endotracheal polyp resolved after antibiotic treatment.
Topics: Ciprofloxacin; Female; Humans; Inflammation; Middle Aged; Polyps; Tracheal Neoplasms | 1993 |
Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Colitis, | 1996 |
Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Colitis, | 1996 |
Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Colitis, | 1996 |
Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Colitis, | 1996 |
Clinical evaluation of technetium-99m infecton for the localisation of bacterial infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Ciprofloxac | 1997 |
Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Bronchi; Cattle; Chromatography, High Pressur | 1999 |
99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Bacterial Infections; Candidiasis; | 2001 |
Dangers of empiric oral ciprofloxacin in the treatment of acute inflammatory diarrhea in children.
Topics: Acute Disease; Anti-Infective Agents; Child; Child, Preschool; Ciprofloxacin; Diarrhea; Empiricism; | 2001 |
Tissue penetration and metabolism of ciprofloxacin.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Blister; Body Fluids; Ciprofloxacin; Hum | 1987 |